Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Vaxart Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
VXRT
Nasdaq
8731
https://vaxart.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Vaxart Inc
Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024?
- Apr 9th, 2024 8:30 pm
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
- Mar 27th, 2024 12:00 pm
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mar 20th, 2024 12:00 pm
Estimating The Intrinsic Value Of Vaxart, Inc. (NASDAQ:VXRT)
- Mar 17th, 2024 2:41 pm
Vaxart, Inc. (NASDAQ:VXRT) Q4 2023 Earnings Call Transcript
- Mar 15th, 2024 5:45 pm
Q4 2023 Vaxart Inc Earnings Call
- Mar 15th, 2024 11:33 am
Vaxart Inc (VXRT) Reports Full Year 2023 Financial Results
- Mar 14th, 2024 9:35 pm
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
- Mar 14th, 2024 8:01 pm
Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14
- Mar 7th, 2024 1:00 pm
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
- Mar 6th, 2024 1:00 pm
VAXART, INC. (VXRT) is a Great Momentum Stock: Should You Buy?
- Feb 26th, 2024 5:00 pm
VAXART, INC. (VXRT) Now Trades Above Golden Cross: Time to Buy?
- Feb 20th, 2024 2:55 pm
Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge
- Feb 5th, 2024 1:00 pm
Strong week for Vaxart (NASDAQ:VXRT) shareholders doesn't alleviate pain of three-year loss
- Feb 1st, 2024 11:42 am
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
- Jan 19th, 2024 1:30 pm
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
- Jan 16th, 2024 2:25 pm
Vaxart, Inc. Announces Management Change
- Jan 16th, 2024 2:22 pm
Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
- Dec 21st, 2023 1:00 pm
Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely
- Nov 7th, 2023 1:46 pm
Vaxart, Inc. (NASDAQ:VXRT) Q3 2023 Earnings Call Transcript
- Nov 3rd, 2023 3:47 pm
Scroll